Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by α2 adrenoceptor blockade

Science

Volumn 286, Issue 5437, 1999, Pages 105-107

  Hertel, Peter ^a   Fagerquist, Maria V ^a   Svensson, Torgny H ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; CLOZAPINE; DOPAMINE; IDAZOXAN; NORADRENALIN; RACLOPRIDE; SEROTONIN;

ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ARTICLE; AVOIDANCE BEHAVIOR; BRAIN CORTEX; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SEROTONIN RELEASE; SUBCUTANEOUS DRUG ADMINISTRATION;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; CATALEPSY; CONDITIONING (PSYCHOLOGY); CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; IDAZOXAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; RACLOPRIDE; RATS; RECEPTORS, ADRENERGIC, ALPHA-2; SALICYLAMIDES; SCHIZOPHRENIA;

ANIMALIA;

EID: 0007673447     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.286.5437.105     Document Type: Article

References (53)

1. A. Carlsson, Neuropsychopharmacology 1, 179 (1988).
2. L. Farde et al., Arch. Gen. Psychiatry 49, 538 (1992).
3. P. A. J. Janssen, C. J. E. Niemeggers, K. H. L. Schellekens, J. Pharmacol. Exp. Ther. 244, 684 (1965); H. Kuribara and S. Tadokoro, Pharmacol. Biochem. Behav. 14, 181 (1981); B. A. Ellenbroek, Pharmacol. Ther. 57, 1 (1993).
4. P. A. J. Janssen, C. J. E. Niemeggers, K. H. L. Schellekens, J. Pharmacol. Exp. Ther. 244, 684 (1965); H. Kuribara and S. Tadokoro, Pharmacol. Biochem. Behav. 14, 181 (1981); B. A. Ellenbroek, Pharmacol. Ther. 57, 1 (1993).
5. P. A. J. Janssen, C. J. E. Niemeggers, K. H. L. Schellekens, J. Pharmacol. Exp. Ther. 244, 684 (1965); H. Kuribara and S. Tadokoro, Pharmacol. Biochem. Behav. 14, 181 (1981); B. A. Ellenbroek, Pharmacol. Ther. 57, 1 (1993).
6. J. Arnt, Acta Pharmacol. Toxicol. 51, 321 (1982).
7. M. L. Wadenberg, E. Ericson, O. Magnusson, S. Ahlenius, Biol. Psychiatry 28, 297 (1990).
8. J. Kane, G. Honigfeld, J. Singer, H. Meltzer, Arch. Gen. Psychiatry 45, 789 (1988).
9. R. J. Baldessarini and F. R. Frankenburg, N. Engl. J. Med. 324, 746 (1991).
10. B. Moghaddam and B. S. Bunney, J. Neurochem. 54, 1755 (1990); G. G. Nomikos, M. Iurlo, J. L. Andersson, K. Kimura, T. H. Svensson, Psychopharmacology 115, 147 (1994); P. Hertel, G. G. Nomikos, M. Iurlo, T. H. Svensson, ibid. 124, 74 (1996); L. Hernandez and B. G. Hoebel, Pharmacol. Biochem. Behav. 52, 581 (1995); M. Volonté, E. Monferini, M. Cerutti, F. Fodritto, F. Borsini, J. Neurochem. 69, 182 (1997); T. Kuroki, H. Y. Meltzer, J. Ichikawa, J. Pharmacol. Exp. Ther. 288, 774 (1999); K. D. Youngren et al., Neuropsychopharmacology 20, 403 (1999).
11. B. Moghaddam and B. S. Bunney, J. Neurochem. 54, 1755 (1990); G. G. Nomikos, M. Iurlo, J. L. Andersson, K. Kimura, T. H. Svensson, Psychopharmacology 115, 147 (1994); P. Hertel, G. G. Nomikos, M. Iurlo, T. H. Svensson, ibid. 124, 74 (1996); L. Hernandez and B. G. Hoebel, Pharmacol. Biochem. Behav. 52, 581 (1995); M. Volonté, E. Monferini, M. Cerutti, F. Fodritto, F. Borsini, J. Neurochem. 69, 182 (1997); T. Kuroki, H. Y. Meltzer, J. Ichikawa, J. Pharmacol. Exp. Ther. 288, 774 (1999); K. D. Youngren et al., Neuropsychopharmacology 20, 403 (1999).
12. B. Moghaddam and B. S. Bunney, J. Neurochem. 54, 1755 (1990); G. G. Nomikos, M. Iurlo, J. L. Andersson, K. Kimura, T. H. Svensson, Psychopharmacology 115, 147 (1994); P. Hertel, G. G. Nomikos, M. Iurlo, T. H. Svensson, ibid. 124, 74 (1996); L. Hernandez and B. G. Hoebel, Pharmacol. Biochem. Behav. 52, 581 (1995); M. Volonté, E. Monferini, M. Cerutti, F. Fodritto, F. Borsini, J. Neurochem. 69, 182 (1997); T. Kuroki, H. Y. Meltzer, J. Ichikawa, J. Pharmacol. Exp. Ther. 288, 774 (1999); K. D. Youngren et al., Neuropsychopharmacology 20, 403 (1999).
13. B. Moghaddam and B. S. Bunney, J. Neurochem. 54, 1755 (1990); G. G. Nomikos, M. Iurlo, J. L. Andersson, K. Kimura, T. H. Svensson, Psychopharmacology 115, 147 (1994); P. Hertel, G. G. Nomikos, M. Iurlo, T. H. Svensson, ibid. 124, 74 (1996); L. Hernandez and B. G. Hoebel, Pharmacol. Biochem. Behav. 52, 581 (1995); M. Volonté, E. Monferini, M. Cerutti, F. Fodritto, F. Borsini, J. Neurochem. 69, 182 (1997); T. Kuroki, H. Y. Meltzer, J. Ichikawa, J. Pharmacol. Exp. Ther. 288, 774 (1999); K. D. Youngren et al., Neuropsychopharmacology 20, 403 (1999).
14. B. Moghaddam and B. S. Bunney, J. Neurochem. 54, 1755 (1990); G. G. Nomikos, M. Iurlo, J. L. Andersson, K. Kimura, T. H. Svensson, Psychopharmacology 115, 147 (1994); P. Hertel, G. G. Nomikos, M. Iurlo, T. H. Svensson, ibid. 124, 74 (1996); L. Hernandez and B. G. Hoebel, Pharmacol. Biochem. Behav. 52, 581 (1995); M. Volonté, E. Monferini, M. Cerutti, F. Fodritto, F. Borsini, J. Neurochem. 69, 182 (1997); T. Kuroki, H. Y. Meltzer, J. Ichikawa, J. Pharmacol. Exp. Ther. 288, 774 (1999); K. D. Youngren et al., Neuropsychopharmacology 20, 403 (1999).
15. B. Moghaddam and B. S. Bunney, J. Neurochem. 54, 1755 (1990); G. G. Nomikos, M. Iurlo, J. L. Andersson, K. Kimura, T. H. Svensson, Psychopharmacology 115, 147 (1994); P. Hertel, G. G. Nomikos, M. Iurlo, T. H. Svensson, ibid. 124, 74 (1996); L. Hernandez and B. G. Hoebel, Pharmacol. Biochem. Behav. 52, 581 (1995); M. Volonté, E. Monferini, M. Cerutti, F. Fodritto, F. Borsini, J. Neurochem. 69, 182 (1997); T. Kuroki, H. Y. Meltzer, J. Ichikawa, J. Pharmacol. Exp. Ther. 288, 774 (1999); K. D. Youngren et al., Neuropsychopharmacology 20, 403 (1999).
16. B. Moghaddam and B. S. Bunney, J. Neurochem. 54, 1755 (1990); G. G. Nomikos, M. Iurlo, J. L. Andersson, K. Kimura, T. H. Svensson, Psychopharmacology 115, 147 (1994); P. Hertel, G. G. Nomikos, M. Iurlo, T. H. Svensson, ibid. 124, 74 (1996); L. Hernandez and B. G. Hoebel, Pharmacol. Biochem. Behav. 52, 581 (1995); M. Volonté, E. Monferini, M. Cerutti, F. Fodritto, F. Borsini, J. Neurochem. 69, 182 (1997); T. Kuroki, H. Y. Meltzer, J. Ichikawa, J. Pharmacol. Exp. Ther. 288, 774 (1999); K. D. Youngren et al., Neuropsychopharmacology 20, 403 (1999).
17. T. J. Brozoski, R. M. Brown, H. E. Rosvold, P. S. Goldman, Science 205, 929 (1979); T. Sawaguchi and P. S. Goldman-Rakic, J. Neurophysiol. 71, 515 (1994); A. F. Arnsten, J. X. Cai, B. L. Murphy, P. S. Goldman-Rakic, Psychopharmacology 116, 143 (1994).
18. T. J. Brozoski, R. M. Brown, H. E. Rosvold, P. S. Goldman, Science 205, 929 (1979); T. Sawaguchi and P. S. Goldman-Rakic, J. Neurophysiol. 71, 515 (1994); A. F. Arnsten, J. X. Cai, B. L. Murphy, P. S. Goldman-Rakic, Psychopharmacology 116, 143 (1994).
19. T. J. Brozoski, R. M. Brown, H. E. Rosvold, P. S. Goldman, Science 205, 929 (1979); T. Sawaguchi and P. S. Goldman-Rakic, J. Neurophysiol. 71, 515 (1994); A. F. Arnsten, J. X. Cai, B. L. Murphy, P. S. Goldman-Rakic, Psychopharmacology 116, 143 (1994).
20. M. F. Green, Am. J. Psychiatry 153, 321 (1996); P. D. Harvey et al., ibid. 155, 1080 (1998).
21. M. F. Green, Am. J. Psychiatry 153, 321 (1996); P. D. Harvey et al., ibid. 155, 1080 (1998).
22. C. R. Ashby and R. Y. Wang, Synapse 24, 349 (1996).
23. R. E. Litman, T. P. Su, W. Z. Potter, W. W. Hong, D. Pickar, Br. J. Psychiatry 168, 571 (1996).
24. D. J. Nutt, J. Psychopharmacol. 8, 193 (1994).
25. J. C. Doxey, A. G. Roach, C. F. Smith, Br. J. Pharmacol. 78, 489 (1983).
26. C. Köhler, H. Hall, S. O. Ögren, L. Gawell, Biochem. Pharmacol. 34, 2251 (1985).
27. P. R. Sanberg, M. D. Bunsey, M. Giordano, A. B. Norman, Behav. Neurosci. 102, 748 (1988).
28. 2, and 1.0 mM sodium phosphate (pH 7.4) at a constant flow rate of 2.5 μl/min. Dialysis samples were injected every 30 or 15 min (for cortical or subcortical dialysis, respectively) and analyzed for dopamine by standard high-performance liquid chromatography coupled to electrochemical detection. The detection limit for dopamine was ∼0.1 fmol/min based on a signal-to-noise ratio of 2:1. Dialysis raw data were calculated as the percentage change from basal concentration, with a value of 100% being defined as the average of the last two pre-injection values, and expressed as the mean ± SEM percentages.
29. P. Hertel, M. V. Fagerquist, T. H. Svensson, data not shown.
30. G. Tanda, V. Bassareo, G. Di Chiara, Psychopharmacology 123, 127 (1996).
31. P. J. Gresch, A. F. Sved, M. J. Zigmond, J. M. Finlay, J. Neurochem. 65, 111 (1995); B. K. Yamamoto and S. Novotney, ibid. 71, 274 (1998).
32. P. J. Gresch, A. F. Sved, M. J. Zigmond, J. M. Finlay, J. Neurochem. 65, 111 (1995); B. K. Yamamoto and S. Novotney, ibid. 71, 274 (1998).
33. E. Carboni, G. L. Tanda, R. Frau, G. Di Chiara, ibid. 55, 1067 (1990); L. Pozzi, R. Invernizzi, L. Cervo, F. Vallebuona, R. Samanin, ibid. 63, 195 (1994).
34. E. Carboni, G. L. Tanda, R. Frau, G. Di Chiara, ibid. 55, 1067 (1990); L. Pozzi, R. Invernizzi, L. Cervo, F. Vallebuona, R. Samanin, ibid. 63, 195 (1994).
35. M. L. Wadenberg and S. Ahlenius, J. Neural Transm. 83, 43 (1991); M. L. Wadenberg, P. Salmi, P. Jimenez, T. Svensson, S. Ahlenius, Eur. Neuropsychopharmacol. 6, 305 (1996).
36. M. L. Wadenberg and S. Ahlenius, J. Neural Transm. 83, 43 (1991); M. L. Wadenberg, P. Salmi, P. Jimenez, T. Svensson, S. Ahlenius, Eur. Neuropsychopharmacol. 6, 305 (1996).
37. The experiment was performed as described (5). In a conventional shuttle-box divided into two compartments, rats were trained to move into the adjacent compartment (response) within 10 s upon presentation of the conditioned stimulus (80 dB white noise) in order to avoid the unconditioned stimulus, an intermittent electric shock in the grid floor. Avoidance was defined as response to the conditioned stimulus within 10 s, and escape as no response to the conditioned stimulus within 10 s but response to the unconditioned stimulus within 60 s. Each training session consisted of 20 trials randomly distributed over 15 min. Only rats that performed avoidance in >80% of the trials after the training sessions were included in subsequent experiments. Experimental sessions were preceded by a pretest session to reaffirm maintenance of the avoidance response. All pretests and experimental sessions consisted of 10 trials randomly distributed over 7.5 min. The avoidance response was calculated and presented as the median (± semi-interquartile range) percent avoidance (the percentage of trials in each session in which the animal performed avoidance). No failures were recorded under any treatment conditions; hence a decrease in avoidance performance was always accompanied by a corresponding increase in escapes.
38. The experiment was performed as described [S. Ahlenius and V. Hillegaart, Pharmacol. Biochem. Behav. 24, 1409 (1986)]. Animals were placed on an inclined (60°) grid and, excluding the first 30 s, the time during which the rat remained in the same position was measured for a maximum of 2.5 min. The catalepsy was scored from 0 to 5 according to the immobility time (square root transformation); score 0 = 0 - 0.08 min, 1 = 0.09 - 0.35 min, 2 = 0.36 -0.80 min, 3 = 0.81 - 1.42 min, 4 = 1.43 - 2.24 min, and 5 ≥ 2.25 min. The catalepsy scores were presented as medians (± semi-interquartile range).
39. H. H. Van Tol et al., Nature 350, 610 (1991).
40. J. Svartengren and M. Celander, Eur. J. Pharmacol. 254, 73 (1994).
41. J. L. Browning, M. L. Wadenberg, K. A. Young, J. Richter, P. B. Hicks, Soc. Neurosci. Abstr. 28, 1741 (1998).
42. J. E. Leysen, P. M. Janssen, A. Schotte, W. H. Luyten, A. A. Megens, Psychopharmacology 112, S40 (1993).
43. J. C. Garratt, F. Crespi, R. Mason, C. A. Marsden, Eur. J. Pharmacol. 193, 87 (1991); P. Hertel, G. G. Nomikos, B. Schilström, L. Arborelius, T. H. Svensson, Neuropsychopharmacology. 17, 44 (1997).
44. J. C. Garratt, F. Crespi, R. Mason, C. A. Marsden, Eur. J. Pharmacol. 193, 87 (1991); P. Hertel, G. G. Nomikos, B. Schilström, L. Arborelius, T. H. Svensson, Neuropsychopharmacology. 17, 44 (1997).
45. E. P. Prinssen, M. S. Kleven, W. Koek, Psychopharmacology 128, 191 (1996).
46. A. Abi-Dargham, M. Laruelle, G. K. Aghajanian, D. Charney, J. Krystal, J. Neuropsychiatry Clin. Neurosci. 9, 1 (1997).
47. D. R. Weinberger, M. S. Aloia, T. E. Goldberg, K. F. Berman, ibid. 6, 419 (1994);
48. R. J. Dolan et al., Nature 378, 180 (1995).
49. J. D. Jentsch et al., Science 277, 953 (1997).
50. J. T. Coull, B. J. Sahakian, J. R. Hodges, Psychopharmacology 123, 239 (1996).
51. J. S. Schneider, Z. Q. Sun, D. P. Roeltgen, Brain Res. 663, 140 (1994).
52. P. Salmi and S. Ahlenius, Eur. J. Pharmacol. 307, 27 (1996).
53. We thank Astra Arcus, Södertälje, Sweden, for providing raclopride. The technical assistance of A. Malmerfelt and A. Olsson is gratefully acknowledged. Supported by the Swedish Medical Research Council (grant number 4747), the Karolinska Institute, and Janssen Research Foundation, Beerse.